Market Dynamics
In the next decade and a half, the Asia Pacific Prothrombin Complex Concentrate (PCC) market is expected to grow substantially due to an increase in demand for anticoagulants in the region. PCC is an anticoagulant drug used in the treatment of severe bleeding episodes caused due to conditions like thrombocytopenia, accompanied by a deficiency in clotting proteins such as factor II, VII, IX, and X. Moreover, the high prevalence of bleeding disorders such as hemophilia and thrombosis in the region also indicates a high market growth potential. The availability of funding for research and development from government bodies and key players is expected to fuel the market growth in the region. Also, there has been an upsurge in the number of clinical trials associated with PCC, indicating positive market outlook. The emergence of generics and biosimilars are also expected to drive the market demand. Various strategies are being adopted by key players for the promotion of their products. One such strategy is the launch of accredited hospitals and awareness campaigns. Companies are also providing discounts to patients and aiding in their treatment costs to increase market penetration.
In addition, factors such as increasing availability of reimbursement policies, rising awareness regarding the benefits of PCC, and increasing healthcare spending in the region are also expected to propel the demand for PCC in the region. On the downside, stringent regulatory policies and high costs of production might impede the growth of the market. Overall, the Asia Pacific PCC market is anticipated to show a positive growth in the forthcoming years due to increasing prevalence of clotting factor deficiencies, increasing government funding towards research & development, and favorable reimbursement policies. Furthermore, the presence of well-established healthcare infrastructure in countries like China and India are expected to drive the global market demand.
